Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting.

Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting.

BACKGROUND: To estimate, from the perspective of the Chinese healthcare system, the economic outcomes of five different first-line strategies among patients with metastatic renal cell carcinoma (mRCC). METHODS AND FINDINGS: A decision-analytic model was developed to simulate the lifetime disease cou...

Full description

Bibliographic Details
Main Authors:	Bin Wu, Baijun Dong, Yuejuan Xu, Qiang Zhang, Jinfang Shen, Huafeng Chen, Wei Xue
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2012-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3297611?pdf=render

Similar Items

Subgroup economic analysis for glioblastoma in a health resource-limited setting.
by: Bin Wu, et al.
Published: (2012-01-01)

Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India
by: Dharna Gupta, et al.
Published: (2023-02-01)

Systemic therapy for metastatic renal cell carcinoma in the first-line setting: Network meta-analysis
by: K. Mori, et al.
Published: (2020-11-01)

Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China.
by: Jingyang Lin, et al.
Published: (2023-01-01)

Editorial: The ever-changing scenario of first line treatment of metastatic renal cell carcinoma
by: Maria Giuseppa Vitale, et al.
Published: (2023-03-01)

Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting
by: Predrag Nikic, et al.
Published: (2022-06-01)

Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study
by: El-Hadaad Hend Ahmed, et al.
Published: (2015-12-01)

Experience of Sorafenib as First-Line Treatment in Metastatic Renal Cell Carcinoma in a Tertiary Care Centre
by: Mohit Saxena, et al.
Published: (2018-07-01)

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
by: Carlo Cattrini, et al.
Published: (2021-10-01)

Prediction for early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors
by: J. Teishima, et al.
Published: (2020-07-01)

Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China
by: Wu Bin, et al.
Published: (2012-11-01)

First-Line Pazopanib Treatment in Metastatic Renal Cell Carcinoma: Real-World Data From a Single Chinese Center
by: Bin Wang, et al.
Published: (2020-10-01)

Impact of Sarcopenia on Survival in Patients Treated with FOLFIRINOX in a First-Line Setting for Metastatic Pancreatic Carcinoma
by: Lisa Lellouche, et al.
Published: (2023-03-01)

Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China
by: Rui Guo, et al.
Published: (2023-12-01)

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
by: Rui Meng, et al.
Published: (2022-03-01)

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
by: Yann-Alexandre Vano, et al.
Published: (2021-11-01)

Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib
by: Paolo Grassi, et al.
Published: (2015-04-01)

Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population
by: Ahmed Badran, et al.
Published: (2020-11-01)

First-line ICIs in renal cell carcinoma
by: Vincenzo Fiorentino, et al.
Published: (2023-08-01)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
by: Giandomenico Roviello, et al.
Published: (2021-07-01)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
by: Kazuyuki Numakura, et al.
Published: (2021-09-01)

First-line sintilimab plus chemotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A cost-effectiveness analysis from China
by: Jian Shen, et al.
Published: (2022-12-01)

Second-Line Treatment of Metastatic Renal Cell Carcinoma in the Era of Predictive Biomarkers
by: Andreea Ioana Parosanu, et al.
Published: (2023-07-01)

Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma
by: Jun Teishima, et al.
Published: (2023-03-01)

Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma
by: Iraklis C. Mitsogiannis, et al.
Published: (2022-09-01)

Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation
by: Shibin Zhu, et al.
Published: (2022-10-01)

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
by: Tassinari E, et al.
Published: (2022-06-01)

Chemotherapy options for metastatic colorectal carcinoma: First, second, third line...
by: Tomašević Zorica I., et al.
Published: (2003-01-01)

Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
by: Ye Wang, et al.
Published: (2022-06-01)

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
by: S De Groot, et al.
Published: (2017-01-01)

Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience
by: Ong, Teng Aik, et al.
Published: (2018)

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab
by: Viktoria Stühler, et al.
Published: (2022-06-01)

Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis
by: Suyang Qin, et al.
Published: (2023-02-01)

Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population
by: Pedro Isaacsson Velho, et al.
Published: (2018-09-01)

Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions
by: Iris Tung, et al.
Published: (2021-08-01)

Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
by: Nicholas A. Bosma, et al.
Published: (2022-03-01)

Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma
by: Kevin K. Zarrabi, et al.
Published: (2022-09-01)

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
by: Jordan Amdahl, et al.
Published: (2017-01-01)

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
by: Zhou C, et al.
Published: (2023-11-01)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022-11-01)